Skip to main content

Table 4 Free fatty acid composition of HCV patients (pre and post) in comparison of controls

From: A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients

Free fatty acids Controls HCV pretreatment patients HCV post treatment patients
C – 14:0 1.5 ± 0.6 2.0 ± 1.1 2.0 ± 0.5
C - 16 : 0 23.8 ± 3.6a 28.6 ± 5.9b 25.8 ± 2.5c
C - 18 : 0 10.8 ± 4.1a 14.4 ± 5.4b 10.2 ± 1.7a
C - 20 : 0 0.5 ± 0.9 0.6 ± 2.1 1.6 ± 1.1
C - 14 : 1 0.1 ± 0.3a NDb 0.2 ± 0.4c
C - 16 : 1 2.8 ± 1.4 3.5 ± 1.5 3.8 ± 1.2
C - 18 : 1 20.7 ± 2.9 19.9 ± 3.9 21.6 ± 2.1
C - 22 : 1 2.2 ± 1.3 2.2 ± 1.3 2.8 ± 1.0
C - 18 : 2 29.9 ± 4.6a 21.2 ± 4.6b 23.8 ± 5.6c
C - 18 : 3 0.4 ± 1.1 0.2 ± 0.6 0.4 ± 0.7
C - 20 : 4 6.1 ± 1.6a 4.4 ± 1.4b 5.3 ± 0.9c
C - 20 : 5 1.0 ± 1.6a 0.4 ± 0.9b NDc
C - 20 : 3 0.2 ± 0.7 0.1 ± 0.5 0.5 ± 1.3
  1. Values represent mean ± Standard deviation of triplicates. Different alphabets on the same row indicate significant difference at p < 0.05
  2. Myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosahexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)